vs
Side-by-side financial comparison of AMERICAN AXLE & MANUFACTURING HOLDINGS INC (AXL) and Hologic (HOLX). Click either name above to swap in a different company.
AMERICAN AXLE & MANUFACTURING HOLDINGS INC is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs -5.4%, a 22.5% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 0.2%). Hologic produced more free cash flow last quarter ($215.2M vs $54.7M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -7.2%).
American Axle & Manufacturing, Inc. (AAM), headquartered in Detroit, Michigan, is an American manufacturer of automobile driveline and drivetrain components and systems.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
AXL vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.0B |
| Net Profit | $-75.3M | $179.1M |
| Gross Margin | 10.2% | 56.0% |
| Operating Margin | -2.4% | 22.6% |
| Net Margin | -5.4% | 17.1% |
| Revenue YoY | 0.2% | 2.5% |
| Net Profit YoY | -449.6% | -10.9% |
| EPS (diluted) | $-0.62 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.4B | $1.0B | ||
| Q3 24 | $1.5B | $988.0M | ||
| Q2 24 | $1.6B | $1.0B | ||
| Q1 24 | $1.6B | $1.0B |
| Q4 25 | $-75.3M | $179.1M | ||
| Q3 25 | $9.2M | $187.2M | ||
| Q2 25 | $39.3M | $194.9M | ||
| Q1 25 | $7.1M | $-17.4M | ||
| Q4 24 | $-13.7M | $201.0M | ||
| Q3 24 | $10.0M | $178.6M | ||
| Q2 24 | $18.2M | $194.5M | ||
| Q1 24 | $20.5M | $169.9M |
| Q4 25 | 10.2% | 56.0% | ||
| Q3 25 | 12.6% | 55.6% | ||
| Q2 25 | 13.1% | 56.3% | ||
| Q1 25 | 12.3% | 37.5% | ||
| Q4 24 | 11.2% | 56.8% | ||
| Q3 24 | 11.4% | 56.4% | ||
| Q2 24 | 13.3% | 55.4% | ||
| Q1 24 | 12.4% | 53.3% |
| Q4 25 | -2.4% | 22.6% | ||
| Q3 25 | 3.2% | 22.6% | ||
| Q2 25 | 3.6% | 24.9% | ||
| Q1 25 | 3.0% | -0.7% | ||
| Q4 24 | 2.6% | 22.5% | ||
| Q3 24 | 2.8% | 23.3% | ||
| Q2 24 | 5.3% | 24.1% | ||
| Q1 24 | 4.8% | 20.7% |
| Q4 25 | -5.4% | 17.1% | ||
| Q3 25 | 0.6% | 17.8% | ||
| Q2 25 | 2.6% | 19.0% | ||
| Q1 25 | 0.5% | -1.7% | ||
| Q4 24 | -1.0% | 19.7% | ||
| Q3 24 | 0.7% | 18.1% | ||
| Q2 24 | 1.1% | 19.2% | ||
| Q1 24 | 1.3% | 16.7% |
| Q4 25 | $-0.62 | $0.79 | ||
| Q3 25 | $0.07 | $0.84 | ||
| Q2 25 | $0.32 | $0.86 | ||
| Q1 25 | $0.06 | $-0.08 | ||
| Q4 24 | $-0.11 | $0.87 | ||
| Q3 24 | $0.08 | $0.75 | ||
| Q2 24 | $0.15 | $0.82 | ||
| Q1 24 | $0.17 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $708.9M | $2.4B |
| Total DebtLower is stronger | $4.0B | $2.5B |
| Stockholders' EquityBook value | $640.0M | $5.2B |
| Total Assets | $6.7B | $9.2B |
| Debt / EquityLower = less leverage | 6.31× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $708.9M | $2.4B | ||
| Q3 25 | $714.1M | $2.2B | ||
| Q2 25 | $586.5M | $1.9B | ||
| Q1 25 | $549.2M | $1.6B | ||
| Q4 24 | $552.9M | $2.0B | ||
| Q3 24 | $542.5M | $2.3B | ||
| Q2 24 | $519.9M | $2.4B | ||
| Q1 24 | $469.8M | $2.2B |
| Q4 25 | $4.0B | $2.5B | ||
| Q3 25 | $2.6B | $2.5B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $2.6B | $2.5B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | $2.6B | $2.5B | ||
| Q2 24 | $2.7B | $2.5B | ||
| Q1 24 | $2.7B | $2.6B |
| Q4 25 | $640.0M | $5.2B | ||
| Q3 25 | $718.4M | $5.0B | ||
| Q2 25 | $673.0M | $4.8B | ||
| Q1 25 | $596.3M | $4.6B | ||
| Q4 24 | $562.8M | $4.8B | ||
| Q3 24 | $616.3M | $5.1B | ||
| Q2 24 | $609.6M | $5.0B | ||
| Q1 24 | $621.4M | $4.8B |
| Q4 25 | $6.7B | $9.2B | ||
| Q3 25 | $5.3B | $9.0B | ||
| Q2 25 | $5.3B | $8.8B | ||
| Q1 25 | $5.1B | $8.5B | ||
| Q4 24 | $5.1B | $8.7B | ||
| Q3 24 | $5.3B | $9.2B | ||
| Q2 24 | $5.3B | $8.9B | ||
| Q1 24 | $5.4B | $8.7B |
| Q4 25 | 6.31× | 0.48× | ||
| Q3 25 | 3.61× | 0.50× | ||
| Q2 25 | 3.86× | 0.52× | ||
| Q1 25 | 4.38× | 0.55× | ||
| Q4 24 | 4.58× | 0.53× | ||
| Q3 24 | 4.28× | 0.49× | ||
| Q2 24 | 4.42× | 0.51× | ||
| Q1 24 | 4.40× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.5M | $229.9M |
| Free Cash FlowOCF − Capex | $54.7M | $215.2M |
| FCF MarginFCF / Revenue | 4.0% | 20.5% |
| Capex IntensityCapex / Revenue | 4.8% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $155.1M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.5M | $229.9M | ||
| Q3 25 | $143.3M | $355.1M | ||
| Q2 25 | $91.9M | $343.3M | ||
| Q1 25 | $55.9M | $169.4M | ||
| Q4 24 | $151.2M | $189.3M | ||
| Q3 24 | $143.6M | $367.0M | ||
| Q2 24 | $142.8M | $405.8M | ||
| Q1 24 | $17.8M | $292.4M |
| Q4 25 | $54.7M | $215.2M | ||
| Q3 25 | $79.2M | $341.4M | ||
| Q2 25 | $34.6M | $330.5M | ||
| Q1 25 | $-13.4M | $153.9M | ||
| Q4 24 | $73.2M | $172.5M | ||
| Q3 24 | $70.4M | $350.6M | ||
| Q2 24 | $94.0M | $385.3M | ||
| Q1 24 | $-30.2M | $279.6M |
| Q4 25 | 4.0% | 20.5% | ||
| Q3 25 | 5.3% | 32.5% | ||
| Q2 25 | 2.3% | 32.3% | ||
| Q1 25 | -0.9% | 15.3% | ||
| Q4 24 | 5.3% | 16.9% | ||
| Q3 24 | 4.7% | 35.5% | ||
| Q2 24 | 5.8% | 38.1% | ||
| Q1 24 | -1.9% | 27.5% |
| Q4 25 | 4.8% | 1.4% | ||
| Q3 25 | 4.3% | 1.3% | ||
| Q2 25 | 3.7% | 1.3% | ||
| Q1 25 | 4.9% | 1.5% | ||
| Q4 24 | 5.6% | 1.6% | ||
| Q3 24 | 4.9% | 1.7% | ||
| Q2 24 | 3.0% | 2.0% | ||
| Q1 24 | 3.0% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | 15.58× | 1.90× | ||
| Q2 25 | 2.34× | 1.76× | ||
| Q1 25 | 7.87× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 14.36× | 2.05× | ||
| Q2 24 | 7.85× | 2.09× | ||
| Q1 24 | 0.87× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXL
| Driveline | $748.4M | 54% |
| Other | $345.7M | 25% |
| Metal Forming | $289.8M | 21% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
